The principle aim of residual disease analysis in patients with chronic myeloid leukaemia
(CML) is to gauge patient response to treatment and, in patients after allogeneic BMT, to …

Quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR) assessing the
amount of transcripts of the BCR/ABL gene, the molecular marker of chronic myeloid …

We identified 243 patients with Philadelphia (Ph) chromosome–positive chronic myeloid
leukemia (CML) who had BCR-ABL transcripts monitored by quantitative reverse …

BACKGROUND. Chronic myeloid leukemia (CML) is a disease characterized by the
presence of a unique molecular marker, ie the fusion gene bcr-abl and its mRNA and protein …

We sought evidence of BCR/ABL transcripts in the peripheral blood of nine CML patients in
complete clinical and cytogenetic remission after treatment by bone marrow transplantation …

To determine the source of residual disease detected in patients with chronic myeloid
leukaemia (CML) in complete cytogenetic remission (n= 8) after treatment with interferon‐α …

The prognostic significance of detecting minimal residual disease by polymerase chain
reaction (PCR) amplification of bcr/abl mRNA transcripts was investigated in 27 bone …

Interferon α (IFN-α) induces cytogenetic responses of variable degree in patients with CML.
We sought to establish the relationship between BCR-ABL transcript numbers measured by …

BACKGROUND AND OBJECTIVE: For purposes of therapeutic decision making, we used
quantitative polymerase chain reaction (PCR) for molecular follow-up of 55 patients with …

Recent progress in the development of diagnostic techniques has greatly facilitated the
monitoring of minimal residual disease (MRD) in patients with hematologic neoplasia. The …